Wells Fargo lifts price targets on Ascendis Pharma and Agilon Health
Wells Fargo kept Overweight ratings on both stocks and raised targets to $330 for Ascendis Pharma and $170 for Agilon Health, TradingView reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Wells Fargo analysts kept their Overweight rating on Ascendis Pharma shares and raised the price target from $326 to $330, a 1.2% increase. According to TradingView, citing Benzinga data, the new target implies 23.6% upside from the November 12 close of $267.07.
Wells Fargo also maintained Overweight on Agilon Health and lifted its target from $146 to $170, a 16.4% rise. The same report says that target points to 54.1% upside from the November 12 close of $110.30.
why it matters
Rating updates like these usually concern individual companies and rarely set the direction for the broader market. For investors, the key point is the bank's view of each company's business outlook rather than a change in macro conditions. Per the same source, price targets from the five most recent Ascendis Pharma analyst notes over the past 30 days ranged from $274 to $356.
tags
instruments
sources
- Wells Fargo maintains Ascendis Pharma at Overweight, raises price target to $330 from $326 — TradingView, 13 November 2026 at 16:22 UTC
- Wells Fargo maintains Agilon Health at Overweight, raises price target to $170 from $146 — TradingView, 13 November 2026 at 16:25 UTC
- Wells Fargo maintains Liftoff Mobile at Overweight, raises price target to $27 from $21 — TradingView, 13 November 2026 at 16:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗